Handelsavisen
prelaunch
Companies Healthcare OTSU.PSX
OT
OTSU.PSX PSX (Pakistan) Pharmaceuticals

Otsuka Pakistan Ltd

$280,20
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
3,7 %
ROE
-2,1 %
Net margin
-2,6 %
Debt / equity
1,37
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Otsuka Pakistan Ltd operates with a debt-to-equity ratio of 1.37, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is assessed as medium, with a current ratio of 1.08, suggesting it has just enough current assets to cover its short-term liabilities. However, the company's free cash flow is negative at -34.84 million PKR, and its operating cash flow is 68.10 million PKR, indicating that while it generates positive cash from operations, capital expenditures are consuming more than that. Profitability metrics show a return on equity (ROE) of -2.07% and a return on assets (ROA) of -0.61%, both of which are negative and significantly below the typical performance of the pharmaceutical industry. These figures suggest that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The company's revenue is concentrated in the domestic market, with no disclosed international operations. This geographic concentration increases exposure to local economic and regulatory risks. The company's revenue of 566.40 million PKR is derived from a single business segment, which is the pharmaceu

Business. Otsuka Pakistan Ltd (OTSU.PSX) is a pharmaceutical company engaged in the research, development, and sale of healthcare products. The firm is headquartered in Pakistan and operates within the broader pharmaceuticals and medical research industry. It is primarily listed on the Pakistan Stock Exchange under the ticker symbol OTSU.PSX. Specific details regarding operating segments or geographic revenue breakdowns are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-2,1 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning OTSU.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to OTSU.PSX. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Otsuka Pakistan Ltd (OTSU.PSX) is a pharmaceutical company engaged in the research, development, and sale of healthcare products. The firm is headquartered in Pakistan and operates within the broader pharmaceuticals and medical research industry. It is primarily listed on the Pakistan Stock Exchange under the ticker symbol OTSU.PSX. Specific details regarding operating segments or geographic revenue breakdowns are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Otsuka Pakistan Ltd operates with a debt-to-equity ratio of 1.37, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is assessed as medium, with a current ratio of 1.08, suggesting it has just enough current assets to cover its short-term liabilities. However, the company's free cash flow is negative at -34.84 million PKR, and its operating cash flow is 68.10 million PKR, indicating that while it generates positive cash from operations, capital expenditures are consuming more than that.

    Profitability metrics show a return on equity (ROE) of -2.07% and a return on assets (ROA) of -0.61%, both of which are negative and significantly below the typical performance of the pharmaceutical industry. These figures suggest that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit.

    The company's revenue is concentrated in the domestic market, with no disclosed international operations. This geographic concentration increases exposure to local economic and regulatory risks. The company's revenue of 566.40 million PKR is derived from a single business segment, which is the pharmaceuticals division. There is no indication of diversification into other therapeutic areas or product lines.

    Looking at the growth trajectory, the company's recent financial performance shows a net loss of 14.58 million PKR, and there is no disclosed revenue growth or expansion into new markets. The capital expenditure of -111.70 million PKR indicates a significant investment in infrastructure or equipment, which may be a precursor to future growth. However, the negative net income and lack of disclosed revenue growth suggest that the company is not currently expanding its market share or increasing its profitability.

    The risk assessment highlights a key flag: the company has negative net cash after subtracting total debt, which could indicate liquidity stress. The dilution risk is assessed as low, with no near-term pressure from share issuance or dilutive events. The company's liquidity risk is moderate, and its credit risk is not explicitly stated but inferred from the debt-to-equity ratio and negative net cash position.

    Recent events include the company's latest financial filing, which discloses the financial snapshot and valuation metrics. There are no recent transcripts or press releases indicating significant operational or strategic changes. The company's financial performance and risk profile suggest a need for close monitoring of its liquidity and profitability trends.

    Key takeaways
    • Otsuka Pakistan Ltd is a pharmaceutical company with a debt-to-equity ratio of 1.37 and a current ratio of 1.08, indicating moderate liquidity and leverage.
    • The company's profitability is weak, with a negative return on equity of -2.07% and a negative return on assets of -0.61%.
    • Revenue is concentrated in the domestic market, with no international operations disclosed, increasing exposure to local economic and regulatory risks.
    • The company's recent financial performance shows a net loss of 14.58 million PKR, and there is no disclosed revenue growth or expansion into new markets.
    • The risk assessment highlights a key flag: the company has negative net cash after subtracting total debt, which could indicate liquidity stress.
    • The company's liquidity risk is moderate, and its credit risk is inferred from the debt-to-equity ratio and negative net cash position.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 5

    Net income surged 681.1% year-over-year to PKR 27.7 million, signaling a strong operational turnaround.

    Revenue grew 19.5% year-over-year to PKR 3.78 billion, demonstrating robust top-line expansion momentum.

    Operating income increased 33.8% year-over-year to PKR 162.9 million, reflecting improved core business profitability.

    Long-term debt decreased significantly from PKR 1.08 billion to PKR 405 million over the four-year period.

    Gross profit reached PKR 863.4 million in the latest period, maintaining a healthy margin above operating costs.

    BEAR CASE · 2

    The company carries a high credit risk flag, indicating significant potential for financial distress or default.

    Debt-to-equity ratio of 1.37 is in the bottom quartile, indicating excessive leverage compared to peers.

    In focus — financials by report

    Valuation FY

    Market price
    $280,20
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $702.8M
    Net cash
    -$965.9M
    Current ratio
    1.1
    Debt / equity
    1.4
    ROA
    -0.6%
    ROE
    -2.1%
    Cash conversion
    -467.0%
    CapEx / revenue
    -19.7%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin3,7 %Below median
    Net Margin-2,6 %Below median
    ROE-2,1 %Below median
    Capex / Rev-19,7 %Bottom quartile
    D/E1,37Bottom quartile
    Cash Conv-4,67Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Otsuka Pakistan Ltd Market data — financials · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    OTSU.PSXCanonical
    PSX (Pakistan) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage